MX2020008454A - Composicion inmunogenica que comprende antigenos estafilococicos. - Google Patents

Composicion inmunogenica que comprende antigenos estafilococicos.

Info

Publication number
MX2020008454A
MX2020008454A MX2020008454A MX2020008454A MX2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A MX 2020008454 A MX2020008454 A MX 2020008454A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
staphylococcal antigens
staphylococcal
antigens
conjugates
Prior art date
Application number
MX2020008454A
Other languages
English (en)
Spanish (es)
Inventor
Fabio Bagnoli
Carine Goraj
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020008454A publication Critical patent/MX2020008454A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2020008454A 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos. MX2020008454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Publications (1)

Publication Number Publication Date
MX2020008454A true MX2020008454A (es) 2021-03-25

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008454A MX2020008454A (es) 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos.

Country Status (15)

Country Link
US (2) US11426455B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752183A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021514387A (cg-RX-API-DMAC7.html)
KR (1) KR20200121825A (cg-RX-API-DMAC7.html)
CN (1) CN112153980A (cg-RX-API-DMAC7.html)
AR (1) AR114627A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019221496B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016373A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090609A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091690A1 (cg-RX-API-DMAC7.html)
GB (1) GB201802339D0 (cg-RX-API-DMAC7.html)
IL (1) IL276661B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020008454A (cg-RX-API-DMAC7.html)
SG (1) SG11202007676RA (cg-RX-API-DMAC7.html)
WO (1) WO2019158537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技(武汉)有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
AU2021262999A1 (en) 2020-05-01 2023-01-19 Sinocelltech Ltd. Method for improving immunogenicity of protein/peptide antigen
KR20220039610A (ko) 2020-09-21 2022-03-29 주식회사 엘지에너지솔루션 리튬 이차전지 활성화 방법 및 리튬 이차전지
CN121081612A (zh) * 2024-05-30 2025-12-09 江苏坤力生物制药有限责任公司 一种金黄色葡萄球菌纳米化抗原、含其的疫苗及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CA2713241C (en) * 2008-01-31 2022-10-04 Timothy Foster Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
AU2011274367B2 (en) * 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
CN106163550A (zh) 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof

Also Published As

Publication number Publication date
SG11202007676RA (en) 2020-09-29
KR20200121825A (ko) 2020-10-26
EA202091690A1 (ru) 2020-11-27
BR112020016373A2 (pt) 2020-12-15
JP2021514387A (ja) 2021-06-10
CA3090609A1 (en) 2019-08-22
IL276661B2 (en) 2023-08-01
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
AR114627A1 (es) 2020-09-30
EP3752183A1 (en) 2020-12-23
US20230052495A1 (en) 2023-02-16
GB201802339D0 (en) 2018-03-28
US20210023192A1 (en) 2021-01-28
AU2019221496A1 (en) 2020-08-27
AU2019221496B2 (en) 2022-12-08
US11426455B2 (en) 2022-08-30
CN112153980A (zh) 2020-12-29
WO2019158537A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
PH12018500037A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GEAP202115055A (en) Anti-cd27 antibodies
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2024013161A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs)
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MX2022001937A (es) Composicion inmunogenica.
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
MX2017016858A (es) Composiciones inmunogenicas.
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
WO2020071869A8 (ko) 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
EP4361262A3 (en) Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis